These findings not only reveal the potential of GLP-1R as a common therapeutic target for AD and DM but also provide a theoretical basis for the development of novel therapies based on the metabolicimmuneneurological axis
Despite considerable progress in the field of psychopharmacology, traditional antidepressant therapies persistently exhibit significant shortcomings, such as delayed therapeutic onset, suboptimal rates of remission, elevated instances of partial response, and adverse side-effect profiles (2, 3)
This is consistent with previous studies providing evidence for hypothalamic control of sympathetic pre-autonomic neurons in the PVN 26 through the use of the same GABA A receptor antagonist 52
25 Given concerns that skeletal muscle loss may predispose patients to long-term metabolic complications, including sarcopenia, it is recommended that individuals undergoing treatment with GLP-1 RAs receive adequate protein intake and appropriate micronutrient supplementation to preserve muscle mass and function, thereby maximizing the clinical benefits of therapy
University of WisconsinWilliam W
Its important to listen to your body and consult a healthcare provider before starting any strict fasting routine
